← Patent-cliff monitor small molecule TRADJENTA LINAGLIPTIN
Loss of exclusivity December 2037 latest FDA-listed patent expiry
Drug detail Brand name TRADJENTA Active ingredient LINAGLIPTIN Strength 5MG Dosage form TABLET Route ORAL Modality Small molecule FDA approval May 2011 Marketing status RX
Listed patents Patent Expires Type 12364700*PED December 2037 — 12364700 June 2037 use U-4224 8853156*PED September 2031 — 8853156 March 2031 product 8846695*PED December 2030 — 8846695 June 2030 use U-1503 11911388 April 2030 use U-3854 10034877*PED February 2030 — 9486526*PED February 2030 — 10034877 August 2029 use U-2347 9486526 August 2029 use U-1915 11033552*PED November 2027 — 8673927*PED November 2027 — 8673927 May 2027 use U-1503 12178819 May 2027 product 11033552 May 2027 product 8883805*PED May 2026 — 8883805 November 2025 product
Regulatory exclusivity Code Expires PED December 2026 M-295 June 2026
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.